Travere Therapeutics (TVTX) Goodwill & Intangibles (2013 - 2026)

Travere Therapeutics has reported Goodwill & Intangibles for 14 years, with the latest figure at $110.0 million in Q1 2026.

• For the quarter ending Q1 2026, Goodwill & Intangibles rose 5.18% year-over-year to $110.0 million; the trailing twelve-month figure through Mar 2026 stood at $110.0 million (up 5.18% YoY), and the FY2025 full-year result was $113.9 million, up 8.68% from the prior year.
• Goodwill & Intangibles for Q1 2026 stood at $110.0 million, down from $113.9 million in the prior quarter.
• The five-year high for Goodwill & Intangibles was $163.8 million in Q1 2023, with the low at $97.9 million in Q4 2022.
• Historically, Goodwill & Intangibles has averaged $120.5 million across 5 years, with a median of $107.7 million in 2023.
• Annual changes were most pronounced in 2024 — Goodwill & Intangibles slumped 37.73% — and 2025, when it advanced 8.68%.
• Travere Therapeutics' Goodwill & Intangibles stood at $97.9 million in 2022, then advanced by 7.53% to $105.2 million in 2023, then retreated by 0.45% to $104.8 million in 2024, then rose by 8.68% to $113.9 million in 2025, then declined by 3.36% to $110.0 million in 2026.
• The last three Goodwill & Intangibles figures came in at $110.0 million (Q1 2026), $113.9 million (Q4 2025), and $110.2 million (Q3 2025), per Business Quant data.